natgillin/translations-raw huggingface dataset:
MSD Α.Φ.Β.Ε.Ε
MSD Α.Φ.Β.Ε.Ε.
MSKCC-prognosescoring (blindet uafhængig central undersøgelse)
MSKCC prognostic score (blinded independent central review)
MSWS-12-score (gennemsnit, SEM) (MS- gangskala)
MSWS-12-score (mean, sem) (Multiple Sclerosis Walking Scale)
MTIC binder sig til DNA’et i cellerne, mens disse reproducerer sig selv, hvorved celledelingen standses.
MTIC binds to the DNA of cells while they are reproducing, which stops cell division.
MTIC hydrolyseres spontant til 5-amino-imidazol-4-carboxamid (AIC), et kendt mellemprodukt i purin- og nucleinsyrebiosyntesen, og til methylhydrazin, som menes at være det aktive alkylerende stof.
MTIC is spontaneously hydrolysed to 5-amino- imidazole-4-carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTIC hydrolyseres spontant til 5-amino-imidazol-4-carboxamid (AIC), et kendt mellemprodukt i purin- og nucleinsyrebiosyntesen, og til methylhydrazin, som menes at være det aktive alkylerende stof.
MTIC is spontaneously hydrolysed to 5-amino-imidazole-4- carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTIC hydrolyseres spontant til 5-amino-imidazol-4-carboxamid (AIC), et kendt mellemprodukt i purin- og nucleinsyrebiosyntesen, og til methylhydrazin, som menes at være det aktive alkylerende stof.
MTIC is spontaneously hydrolyzed to 5-amino- imidazole-4-carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTIC hydrolyseres spontant til 5-amino-imidazol-4-carboxamid (AIC), et kendt mellemprodukt i purin- og nucleinsyrebiosyntesen, og til methylhydrazin, som menes at være det aktive alkylerende stof.
MTIC is spontaneously hydrolyzed to 5-amino-imidazole-4- carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTIC hydrolyseres spontant til 5-amino-imidazol-4-carboxamid (AIC), et kendt mellemprodukt i purin- og nucleinsyrebiosyntesen, og til methylhydrazin, som menes at være det aktive alkylerende stof.
MTIC is spontaneously hydrolyzed to 5amino-imidazole4carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTIC hydrolyseres spontant til 5-amino-imidazol-4-carboxamid (AIC), et kendt mellemprodukt i purin- og nukleinsyrebiosyntesen, og til methylhydrazin, som menes at være det aktive alkylerende stof.
MTIC is spontaneously hydrolyzed to 5-amino-imidazole-4- carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species.
MTICs cytotoksiske effekt formodes primært at skyldes alkyleringen ved O6-positionen i guanin med ledsagende alkylering ved N7-positionen.
The cytotoxicity of MTIC is thought to be due primarily to alkylation at the O6 position of guanine with additional alkylation also occurring at the N7 position.
MTIC’ s cytotoksiske effekt formodes primært at skyldes alkyleringen ved O6-positionen i guanin med ledsagende alkylering ved N7-positionen.
The cytotoxicity of MTIC is thought to be due primarily to alkylation at the O6 position of guanine with additional alkylation also occurring at the N7 position.
MTIC’ s cytotoksiske effekt formodes primært at skyldes alkyleringen ved O6-positionen i guanin med ledsagende alkylering ved N7-positionen.
The cytotoxicity of MTIC is thought to be dueprimarily to alkylation at the O6 position of guanine with additional alkylation also occurring at the N7 position.
MTIC’s cytotoksiske effekt formodes primært at skyldes alkyleringen ved O6-positionen i guanin med ledsagende alkylering ved N7-positionen.
The cytotoxicity of MTIC is thought to be due primarily to alkylation at the O6 position of guanine with additional alkylation also occurring at the N7 position.
MTX - Methotrexat
MTX - Methotrexate
MTX 1,5 g/m2 i.v. (24 timer), dag 1;
MTX 1.5 g/m2 i.v. (24 h), day 1;
MTX 1,5 g/m² i.v. (24 timer), dag 1;
MTX 1.5 g/m2 i.v. (24 h), day 1;
MTX 12 mg intrathecal, dag 1
MTX 12 mg intrathecal, day 1
MTX 15 mg intrathecal, dag 1
MTX 15 mg intrathecal, day 1
MTX 15 mg intrathecal, dag 1;
MTX 15 mg intrathecal, day 1;
MTX 500 mg/m2 i.v. (24 timer), dag 1, 15;
MTX 500 mg/m2 i.v. (24 h), days 1, 15;
MTX 500 mg/m2 i.v. (24 timer), dag 1, 15; 6-
MTX 500 mg/m2 i.v. (24 h), days 1, 15;
MTX 500 mg/m² i.v. (24 timer), dag 1, 15;
MTX 500 mg/m2 i.v. (24 h), days 1, 15;
MTX n=257 (95% konfidens- interval)
MTX n=257 (95% confidence interval)
MTX) i kombination med RoActemra.
MTX) were used in combination with RoActemra.
MTX) til tocilizumab monoterapi medførte en øget hyppighed af disse stigninger.
MTX) to tocilizumab monotherapy resulted in increased frequency of these elevations.
MU: Million enheder
MU: Million Units
Muckle-Wells syndrom (MWS)
Muckle-Wells Syndrome (MWS)
Muckle-Wells syndrom (MWS)
Muckle-Wells Syndrome (MWS),
Muckle-Wells syndrom (MWS),
Muckle-Wells Syndrome (MWS),
Mucosa-
Oedemax
Mucosaheling
Mucosal healing
Mucosaheling¶
Mucosal healing¶
Mucositis
symptoms
Mucositis Opkastning Diarré Kvalme
Mucositis Vomiting Diarrhoea Nausea
Mucositis/slimhinde- inflammation Smerter†
Mucositis/mucosal inflammation
Muenchen Bayern, 85748 Tyskland
Muenchen Bayern, 85748 Germany
Mujeres en edad fértil / Anticoncepción en hombres y mujeres
Women of childbearing potential / Contraception in males and females
Mukokutane reaktioner (herunder Stevens-Johnsons syndrom)*
Mucocutaneous reaction (including Stevens Johnson Syndrome)
Mukokutane reaktioner, herunder Stevens-Johnsons syndrom
Mucocutaneous reactions, including Stevens-Johnson Syndrome
mukolytika og til sidst Cayston.
mucolytics and lastly, Cayston.
Mukosal inflammation, smerter i ekstremiteterne, smerter, kuldegysninger, brystsmerter,
Hiccups, Pharyngolaryngeal pain, Dysphonia
Mukositis eller obstipation grad 2  5 dage eller  grad 3 af en hvilken som helst varighed1
Mucositis or Constipation Grade 2  5 days or Grade  3 any duration1
Mulhuddart Dublin 15 Irland
Mulhuddart Dublin 15
Mulhuddart Dublin 15 Irland
Mulhuddart Dublin 15 Ireland
Mulhuddart Dublin 15 Irland
Mulhuddart Dublin 15 Ireland.
Mulhuddart Dublin 15 Irland
Mulhuddart, Dublin 15, Ireland.
Mulhuddart, Dublin 15 Irland
Mulhuddart, Dublin 15 Ireland
mulig forhøjelse af midazolams
Invirase/ritonavir due to the potential
Mulig interaktion med andre hæmatopoietiske vækstfaktorer og cytokiner er ikke blevet undersøgt i kliniske forsøg.
Possible interactions with other haematopoietic growth factors and cytokines have not yet been investigated in clinical trials.
Mulig interaktion med orale kontraceptiva samt øget risiko for tromboemboli.
Possible interaction with oral contraceptives and increased risk of thromboembolism
Mulig interaktion mellem lamivudin og cladribin på grund af hæmning af lamivudins intracellulære fosforylering af cladribin.
Possible interaction between lamivudine and cladribine due to inhibition of intracellular phosphorylation of cladribine by lamivudine.
Mulig påvirkning af hæmostasen (se ovenfor).
Potential effects on haemostasis (see above).
mulig resistens over for maraviroc.
possible resistance to maraviroc.
mulig resistens over for maraviroc.
resistance to maraviroc.
Mulig risiko for maligniteter:
Potential risk of malignancies;
Mulig risiko for teratogenicitet
Potential risk of teratogenicity
Mulig  eller  af antitrombotisk virkning.
antithrombotic effect.
Mulige alvorlige bivirkninger.
Some side effects could be serious.
Mulige alvorlige bivirkninger:
Serious side effects include:
Mulige bivirkninger
Potential undesirable effects
Mulige Bivirkninger af probenecid
Possible side effects of taking probenecid
Mulige bivirkninger er anført nedenfor og grupperet efter hyppighed:
Possible side effects listed below are grouped by frequency of occurrence:
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel.Du ellerdine pårørende kan også indberette bivirkninger direkte til Sundhedsstyrelsen via det nationale rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af dette lægemiddel.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
mulige dosis digoxin, hvis der skal
possible dose of digoxin should
Mulige effektor medierede celle lysis mekanismer inkluderer komplement afhængig cellulær cytotoksicitet (CDC) som et resultat af C1q binding og antistof afhængig cellulær cytotoksicitet (ADCC) medieret ved en eller flere af Fc receptorerne på overfladen af granulocytter, makrofager og NK celler.
Possible mechanisms of effector-mediated cell lysis include complement-dependent cytotoxicity (CDC) resulting from C1q binding, and antibody-dependent cellular cytotoxicity (ADCC) mediated by one or more of the Fc receptors on the surface of granulocytes, macrophages and NK cells.
Mulige effektormedierede cellelysemekanismer inkluderer komplementafhængig cytotoksicitet (CDC) som et resultat af C1q-binding og antistofafhængig cellulær cytotoksicitet (ADCC) medieret ved en eller flere Fc-receptorer på overfladen af granulocytter, makrofager og NK-celler.
Possible mechanisms of effector-mediated cell lysis include complement-dependent cytotoxicity (CDC) resulting from C1q binding, and antibody-dependent cellular cytotoxicity (ADCC) mediated by one or more of the Fc receptors on the surface of granulocytes, macrophages and NK cells.
Mulige interaktioner med andre aktive lægemidler, der vides at have høj affinitet til plasmaproteiner, bør derfor overvejes (f.eks.
Possible interactions with other active substances known to have high affinity for plasma proteins should be considered (e.g.
Mulige interaktioner med andre hæmatopoietiske vækstfaktorer og cytokiner er ikke undersøgt i kliniske studier.
Possible interactions with other haematopoietic growth factors and cytokines have not yet been investigated in clinical trials.
Mulige komplikationer kan ofte undgås ved at sikre, at patienten:
Potential complications can often be avoided by ensuring that patients:
Mulige komplikationer kan ofte undgås ved at sikre, at patienterne:
Potential complications can often be avoided by ensuring that patients:
Mulige korte afstande ud over ISM-bånd, giver ikke bedre anvendelse i denne tabel.
Possible shorter distances outside ISM bands are not considered to have a better applicability of this table.
Mulige livstruende anafylaktiske/anafylaktoide reaktioner er forekommet med faktor- IX produkter, inklusive BeneFIX.
Potentially life-threatening anaphylactic/anaphylactoid reactions have occurred with factor IX products, including BeneFIX.
Mulige lægemiddelinteraktioner, der kan påvirke zonisamid
Potential medicinal product interactions affecting zonisamide
Mulige overfølsomhedsreaktioner (f.eks. pruritus, erythema), herunder et tilfælde med generaliseret kløe, udslæt og dyspnø, er blevet rapporteret i kliniske studier med albiglutid.
Possible hypersensitivity reactions (e.g. pruritus, erythema), including a case with generalised pruritus and rash with dyspnoea, have been reported in clinical trials with albiglutide.
Mulige patienter til disse undersøgelser havde kronisk hepatitis C bekræftet ved en positiv HCV-RNA-polymerasekædereaktionstest (PCR) (> 30 IE/ml), en leverbiopsi i overensstemmelse med en histologisk diagnose med kronisk hepatitis uden anden årsag til den kroniske hepatitis, samt en abnorm serum ALAT.
Eligible patients for these trials had chronic hepatitis C confirmed by a positive HCV- RNA polymerase chain reaction assay (PCR) (> 30 IU/mL), a liver biopsy consistent with a histological diagnosis of chronic hepatitis with no other cause for the chronic hepatitis, and abnormal serum ALT.
Mulige patienter til disse undersøgelser havde kronisk hepatitis C bekræftet ved en positiv HCV-RNA-polymerasekædereaktionstest (PCR) (> 30 IE/ml), en leverbiopsi i overensstemmelse med en histologisk diagnose med kronisk hepatitis uden anden årsag til den kroniske hepatitis, samt en abnorm serum ALAT.
Eligible patients for these trials had chronic hepatitis C confirmed by a positive HCV-RNA polymerase chain reaction assay (PCR) (> 30 IU/ml), a liver biopsy consistent with a histological diagnosis of chronic hepatitis with no other cause for the chronic hepatitis, and abnormal serum ALT.
Mulige problemer
Possible problems
mulige påvirkninger ved at skifte til andre tidszoner.
The possible effects of changing to different time zones.
Mulige relaterede bivirkninger, der er blevet rapporteret i kliniske forsøg eller efter markedsføring med IOA, er anført i tabellen nedenfor.
Possibly related adverse reactions that have been reported in clinical trials or during postmarketing use with IOA are listed in the table below.
Mulige systemiske virkninger omfatter Cushings syndrom, cushingoide træk, adrenal suppression, nedsat knoglemineraltæthed, katarakt og glaukom samt sjældnere en række psykiske eller adfærdsmæssige virkninger, herunder psykomotorisk hyperaktivitet, søvnforstyrrelser, angst, depression eller aggression (især hos børn) (se underafsnittet Pædiatrisk population nedenfor for oplysninger om systemiske virkninger af inhalerede kortikosteroider hos børn og unge).
Possible systemic effects include Cushing’s syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, cataract and glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children) (see Paediatric population sub-heading below for information on the systemic effects of inhaled corticosteroids in children and adolescents).
Mulige systemiske virkninger omfatter Cushings syndrom, cushingoide træk, adrenal suppression, nedsat knoglemineraltæthed, katarakt og glaukom samt sjældnere en række psykiske eller adfærdsmæssige virkninger, herunder psykomotorisk hyperaktivitet, søvnforstyrrelser, angst, depression eller aggression (især hos børn) (se underafsnittet ”Pædiatrisk population” nedenfor for oplysninger om systemiske virkninger af inhalerede kortikosteroider hos børn og unge).
Possible systemic effects include Cushing’s syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, cataract and glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children) (see Paediatric population sub-heading below for information on the systemic effects of inhaled corticosteroids in children and adolescents).
Mulige tegn på dehydering er anført øverst i punkt 4 "Bivirkninger".
Possible signs of dehydration are listed at the top of section 4, ‘Possible side effects’.
Mulige tegn på dehydrering er anført øverst i punkt 4, "Bivirkninger".
Possible signs of dehydration are listed at the top of section 4, ‘Possible side effects’.
Mulige tegn på dehydrering:
Possible signs of dehydration are:
Mulige tegn på for stort væsketab fra kroppen er anført i afsnit 4, “Bivirkninger” andre lægemidler der sænker blodsukkeret, som f.eks. insulin eller et “sulfonylurinstof”.
Possible signs of losing too much fluid from your body are listed in section 4 ‘Possible side effects’. other medicines that lower the amount of sugar in your blood such as insulin or a “sulphonylurea” medicine.
Mulige tegn på for stort væsketab fra kroppen er anført øverst i punkt 4 "Bivirkninger". hvis du tager medicin, som indeholder et af følgende aktive stoffer:
Possible signs of losing too much fluid from your body are listed at the top of section 4 ‘Possible side effects’. if you are using medicines containing any of the following active substances:
Mulige tegn på laktatacidose:
Possible signs of lactic acidosis are:
Mulige tegn på lavt blodsukker:
Possible signs of low blood sugar are:
Mulige tegn på overdrevent væsketab fra kroppen er anført øverst i punkt 4, "Bivirkninger". hvis du tager anden medicin, som sænker sukkerindholdet i blodet, såsom insulin eller et ”sulfonylurinstof”.
Possible signs of losing too much fluid from your body are listed at the top of section 4 ‘Possible side effects’. if you are taking other medicines that lower the amount of sugar in your blood such as insulin or a “sulphonylurea” medicine.
mulige virkninger af at rejse i forskellige tidszoner,
the possible effects of changing to different time zones,
Mulighed 1 / Sprøjte: Der omrøres forsigtigt i fem minutter, hvorefter blandingen af korn af cysteamin og sur frugtjuice suges op i en doseringssprøjte.
Option 1 / Syringe: Mix gently for 5 minutes, then aspirate the mixture of cysteamine granules and acidic fruit juice into a dosing syringe.
Mulighed 2 / Kop: Blandingen omrøres forsigtigt i fem minutter i en kop eller rystes forsigtigt i fem minutter i en kop med låg (f.eks. med drikketud).
Option 2 / Cup: Mix gently for 5 minutes in a cup or shake gently for 5 minutes in a covered cup (e.g., “sippy” cup).
mulighed for at voriconazol kan øge
may increase the plasma
Mulighed for interaktion efter intramuskulær injektion
Potential for interaction following intramuscular injection
Mulighed for, at andre lægemidler påvirker lumacaftor/ivacaftor
Potential for other medicinal products to affect lumacaftor/ivacaftor
Mulighed for, at andre lægemidler påvirker rufinamid
Potential for other medicinal products to affect rufinamide
Mulighed for, at lumacaftor/ivacaftor påvirker andre lægemidler
Potential for lumacaftor/ivacaftor to affect other medicinal products
Mulighed for, at lumacaftor/ivacaftor påvirker transportere
Potential for lumacaftor/ivacaftor to interact with transporters
Mulighed for, at rufinamid påvirker andre lægemidler
Potential for rufinamide to affect other medicinal products
Muligheden for afkortelse af behandlingsvarigheden til 16 uger hos patienter med genotype 2 eller 3 blev undersøgt, baseret på et vedvarende virologisk respons hos patienter, som havde et hurtigt virologisk respons ved uge 4 i studie NV17317 (se tabel 16).
The possibility of shortening treatment duration to 16 weeks in genotype 2 or 3 patients was examined based on a sustained virological response observed in patients with rapid virological response by week 4 in study NV17317 (see Table 16).
Muligheden for anafylaktisk reaktion over for PEG 400 kan dog ikke udelukkes.
However, the possibility of anaphylactic reaction related to PEG400 cannot be excluded.
Muligheden for at abacavir øger risikoen for at få et hjertetilfælde, kan ikke udelukkes.
The possibility that abacavir increases the risk of having a heart attack cannot be excluded.
Muligheden for at inkludere patienter i registerstudiet for at facilitere indsamlingen af data vedrørende langtidseffekt og sikkerhed;
The possibility to include patients in the registry study to facilitate the collection of long term efficacy and safety data;
Muligheden for at inkludere patienterne i registerstudiet, for at facilitere indsamlingen af data for virkning og sikkerhed på langt sigt;
The possibility to include patients in the registry study to facilitate the collection of long term efficacy and safety data;
muligheden for at købe din insulin i det land, som du skal besøge,
the availability of your insulin in the country you are visiting,
Muligheden for at sevofluran kan udløse episoder med malign hypertermi hos modtagelige hunde kan ikke udelukkes
The possibility of sevoflurane triggering episodes of malignant hyperthermia in susceptible dogs cannot be ruled out.
Muligheden for at sevofluran kan udløse episoder med malign hypertermi hos modtagelige hunde kan ikke udelukkes.
The possibility of sevoflurane triggering episodes of malignant hyperthermia in susceptible dogs cannot be ruled out.
Muligheden for en interaktion kan ikke udelukkes, og blodkoncentrationerne af ciclosporin, mycophenolatmofetil og tacrolimus skal overvågges nøje under anvendelse af disse kombinationer og efter ophør.
The possibility of an interaction cannot be excluded and a close monitoring of blood concentrations of ciclosporin, mycophenolate mofetil and tacrolimus should be considered during the use of combination and after its withdrawal.
Muligheden for hypersensitivitet, herunder svære livstruende eller fatale anafylaktiske/anafylaktoide reaktio- ner, bør altid haves for øje.
The possibility of hypersensitivity including severe life-threatening fatal anaphylactic / anaphylactoid reactions must always be considered.
Muligheden for interaktioner med gonadotropiner eller produkter, der kan fremkalde frigivelse af histamin i modtagelige personer, kan imidlertid ikke helt udelukkes.
However, the possibility of interactions with gonadotropins or products that may induce histamine release in susceptible individuals, cannot be totally excluded.
Muligheden for interaktioner med lægemidler ved P-gp’s bindingssted vil sandsynligvis afhænge af denne transportørs hæmningsgrad.
The potential for drug interactions at the P-gp site will likely depend on the degree of inhibition of this transporter.
Muligheden for interaktioner med lægemidler ved P-gp’s bindingssted vil sandsynligvis afhænge af i hvor stor udstrækning denne transportør hæmmes.
The potential for drug interactions at the P-gp site will likely depend on the degree of inhibition of this transporter.
Muligheden for interaktioner med lægemidler ved P-gp’s bindingssted vil sandsynligvis afhænge af, i hvor stor udstrækning denne transportør hæmmes.
The potential for drug interactions at the P-gp site will likely depend on the degree of inhibition of this transporter.
Muligheden for kirurgiske og kliniske komplikationer samt hvordan man skal reagere i tilfælde af, at sådanne komplikationer opstår.
The potential for surgical and clinical complications and how to respond in the event any such complications arise.
Muligheden for lægemiddelinteraktioner ved P-gp’s bindingssted vil sandsynligvis afhænge af denne transportørs hæmningsgrad.
The potential for drug interactions at the P-gp site will likely depend on the degree of inhibition of this transporter.
Muligheden for lægemiddelinteraktioner ved P-gp’s bindingssted vil sandsynligvis afhænge af, i hvor stor udstrækning denne transportør hæmmes.
The potential for drug interactions at the P-gp site will likely depend on the degree of inhibition of this transporter.
Muligheden for osteonekrose af øregangen skal overvejes hos patienter, der får behandling med bisfosfonater, og som udviser øresymptomer, herunder kroniske øreinfektioner.
The possibility of osteonecrosis of the external auditory canal should be considered in patients receiving bisphosphonates who present with ear symptoms including chronic ear infections t.
Muligheden for P450-medierede interaktioner med andre lægemidler, som involverer abacavir, er lille baseret på resultater af in vitro studier og de kendte betydende metaboliseringsveje for abacavir.
Based on the results of in vitro experiments and the known major metabolic pathways of abacavir, the potential for P450 mediated interactions with other medicinal products involving abacavir is low.
Muligheden for Pneumocystis jiroveci-pneumoni skal overvejes, hvis en patient har lungesymptomer.
If a patient presents with pulmonary symptoms, the possibility of pneumocystis carinii pneumonia should be taken into account.
Muligheden for, at der opstår hæmolytisk anæmi i forbindelse med cefalosporiner, herunder Zinforo- behandlingen, kan imidlertid ikke udelukkes.
However, the possibility that haemolytic anaemia may occur in association with cephalosporins including Zinforo treatment cannot be ruled out.
muligvis
1.21
Muligvis
possible
Muligvis blokerer alfa-interferoner også formeringen af virus.
Alfa interferons may also block the multiplication of viruses.
muligvis ikke giver en optimal
may not provide an optimal
muligvis ikke giver en optimal
of 150 mg may not provide an